Marea Therapeutics

Marea is a biotechnology company focused on developing next-generation treatments for cardiometabolic diseases, which are the leading cause of morbidity and mortality worldwide. The company leverages the latest advances in human genetic data to identify, create, and develop novel therapies aimed at addressing the underlying biology of these diseases, rather than just managing symptoms. Marea's therapies are designed to complement existing treatments and provide transformative options for patients who remain at high risk despite current therapies. The company operates in the biopharmaceutical market and serves patients with cardiometabolic conditions, including those at risk for heart attacks even after controlling for traditional risk factors like obesity and elevated LDL cholesterol. Marea's business model involves advancing multiple undisclosed discovery programs that utilize strong human genetics and other validated targets. The company generates revenue through the development and potential commercialization of these novel therapies. Led by a team of experienced scientists and biopharma executives, Marea aims to make a significant impact on the lives of millions of people living with cardiometabolic diseases.

Keywords: cardiometabolic diseases, human genetics, novel therapies, biopharmaceutical, biotechnology, heart attacks, adipose biology, drug development, patient risk, transformative treatments.